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Modern anesthetics work like a miracle,
providing the comprehensive nerve
blockade required for millions of surgeries
performed every day. Modern analgesics,
in contrast, haven’t progressed much
beyond folk remedies: among the most
widely used pain relief drugs are morphine
and other compounds derived from the
opium poppy. While effective for short-
term, acute pain, their long-term use
leads to tolerance, dependence, and
severe side effects. They offer little help
to treat the chronic pain that afflicts nearly
one in four Americans and costs the US
nearly $100 billion each year. In the quest
for a better solution, researchers are
developing compounds to modulate the
nerve ion channels that help carry pain
signals to the brain. One of these new
drugs is already in the market for severe,
morphine-resistant chronic pain, while
many others have shown promise. ‘‘Ion
channel modulators and other emerging
therapeutics could help address the
unmet challenge of treating chronic pain,’’
says Andy Dray, Ph.D., chief scientist at
AstraZeneca R&D in Montreal.
This challenge is manifold. Chronic pain
often stems from nerve or tissue damage
caused by injury, infection, cancer, dia-
betes, or other conditions. What trans-
forms acute pain from an injury into chronic
pain is poorly understood, and the under-
lying mechanisms change over time.
‘‘Chronic pain is a moving target,’’ says
Michael Gold, Ph.D., a pain researcher at
the University of Pittsburgh. Further, it is
hard to tease out the molecules and
pathways involved in the pain sensation
from those involved in other vital biological
processes. ‘‘That’s why the drugs we have
for chronic pain are not consistently effec-
tive and can have serious side effects,’’
says Gold. Finally, the maladaptive changes
in the nervous system that underlie
chronic pain can resist efforts to reverse
them. ‘‘Pharmacological interventions may
provide short term relief,’’ he says. ‘‘How-
ever, once the nervous system has
acquired a new ‘state’ associated with
chronic pain, it can find ways to get back
to it.’’
In the past, as Dray points out, pain relief
drugs were typically discovered by ‘‘clin-
ical serendipity’’: compounds developed
for other conditions such as depression
(e.g. amitriptyline), epilepsy (e.g. gabapen-
tin), and arrhythmia (e.g. mexiletine) were
found to relieve pain as well. While these
drugs offer an alternative to opioids, they
are only moderately effective and come
with their own baggage of side effects.
Fortunately, newly emerging drugs based
on rational design and direct targeting of
specific pain processes promise better
outcomes. A dramatic early example is
ziconotide (Prialt), approved in 2004 for
treating severe, morphine-resistant pain
due to cancer or AIDS. The drug works
by blocking N-type calcium channels,
which are critical for the transmission of
the pain signal. ‘‘It literally works miracles
for patients in agony from severe, intrac-
table cancer pain,’’ says Gary Bennett,
PhD, a pain researcher at McGill Univer-
sity. ‘‘Fifteen minutes after getting it, they
smile and say ‘the pain is gone!’’’
Morphine and other opioids activate
m-opioid receptors in the body, initiating
cellular processes that result in the block
of N-type calcium channels. Cannabis
and the body’s own cannabinoids do like-
wise to create their psychoactive effect.
‘‘Mother nature is already blocking the N-
type channel as a way to alleviate pain,’’
says Terrance Snutch, Ph.D., a University
of British Columbia researcher who was
the first to clone this channel. As zicono-
tide operates directly on N-type channels,
which are downstream of and more limited
in distribution than opioid receptors, it
avoids most opioid side effects. Nor
does it create tolerance or dependence
even after years of use. Unfortunately, as
Snutch points out, ziconotide has its own
limitations. Derived from the toxin of
a fish-hunting cone snail, it’s a large poly-
peptide molecule that has to be infused
into the patient’s spine using a surgically
implanted pump—a far cry from the oral
pill that pain sufferers are hoping for.
In 2006, Neuromed Pharmaceuticals, a
company founded by Snutch, devel-
oped an orally available calcium channel
blocker called NMED-160 that it licensed
to Merck. Although this compound fared
well in safety trials, Merck did not advance
it further, citing lack of ‘‘ideal pharmaceu-
tical characteristics.’’ However, Neu-
romed is actively developing other simi-
larly acting compounds that may emerge
as a viable alternative to ziconotide.
Further upstream in the pain pathway,
and easier to reach, are the voltage-gated
sodium channels that help generate the
pain signal and tend to become hyperex-
citable in chronic pain, epilepsy, and other
conditions. ‘‘Because sodium channels
are involved in the generation of the action
potentials, they are very important drug
targets,’’ says Manoj Patel, Ph.D., who
studies these channels at the University
of Virgina. Among the nine voltage-gated
sodium channel isoforms identified so
far, two (Nav1.7 and Nav1.8) have emerged
as important targets in pain, while others
have cardiac, motor, and other roles.
Broad-spectrum sodium channel block-
ade with drugs such as the local anes-
thetic lidocaine and the anticonvulsant
carbamazepine has been shown to relieve
chronic pain; however, such nonselective
blockers can disrupt other vital functions
in the body. ‘‘That’s why toxicity is a big
problem when using them to treat pain,’’
says Patel.
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is exclusively present in pain-sensing
neurons, may be a better option. In 2007,
researchers at Abbott discovered a
molecule, A-803467, that is a 100-fold
more potent at blocking Nav1.8 than
other sodium channels. Although Abbott
stopped clinical development on the
compound due to poor bioavailability,
preclinical results were impressive. ‘‘That
was a good proof-of-concept that it’s
possible to develop a highly isoform-
selective blocker,’’ says Theodore Cum-
mins, Ph.D., who studies the biophysics
of ion channels at Indiana University. A
number of companies including Merck,
AstraZeneca, and GlaxoSmithKline are
now in the hunt for a viable Nav1.8 blocker.
The Nav1.7 isoform sprang into promi-
nence in 2006 from a study of certain
families in Pakistan whose members are
remarkable for their total inability to feel
pain. These individuals, who often amaze
spectators by walking on burning coals or
driving spikes through their bodies, are
otherwise fairly normal, although they
typically die young due to unattended
injuries and infections. It turns out that
they owe their unusual trait to a loss-of-
function mutation in the Nav1.7 gene.
Interestingly, and perhaps logically, it
turns out that people with a gain-of-func-
tion mutation in the same gene suffer
from an exaggerated pain response.
Taken together, ‘‘that’s the best validation
that Nav1.7 might be an ideal target for
pain therapies,’’ says Cummins. However,
efforts to find a safe and effective Nav1.7
blocker have failed, in part because
this isoform is less structurally distinct
and less pain-specialized than Nav1.8.
‘‘Modulating and knocking down the
channel may be a better approach,’’ says
Cummins. In 2008, Merck researchers
reported that a tarantula venom peptide,
ProTx-II, does precisely that: by binding
to the channel’s voltage sensor, it in-
creases the membrane voltage needed
to activate it. This finding offers hope offinding pain drugs based on selective
Nav1.7 inhibition, says Cummins.
Still further upstream in the pain
pathway, at nerve terminal membranes,
lie the receptors and ion channels that
translate noxious stimuli such as heat,
cold, pressure, or acidity into nerve signals.
A key player among them is the transient
receptor potential V1 (TRPV1) channel,
a ligand-gated channel activated by
noxious heat and acidity. It also responds
to capsaicin, the compound that makes
chili peppers ‘‘hot.’’ Normally responsive
only to strong stimuli, this channel, like
some sodium channels, tends to become
hypersensitivewhen inflammation or tissue
damage is present. Knocking out or inhibit-
ing it improves pain resistance in some
animal models. Driven by this rationale,
pharmaceutical companies have devel-
oped a range of compounds that block
the TRPV1 channel. These can typically
be taken orally and some have shown ther-
apeutic value. Unfortunately, it so happens
that the channel also exists in the hypothal-
amus, where it helps regulate body
temperature. Consequently, TRPV1 antag-
onists cause persistent fever in many
patients. ‘‘You particularly don’t want that
in a postoperative setting, as it would
mimic an infection,’’ says Clifford Woolf,
M.D., Ph.D., of Harvard Medical School.
While several companies including
Eli Lilly, Amgen, and AstraZeneca are
exploring ways to improve TRPV1 antago-
nists, others are taking the opposite
approach: exploiting TRPV1 agonists
such as capsaicin. By overstimulating the
TRPV1 receptor, and causing an initial
burning sensation, these compounds can
create the inverse effect of desensitizing
a target area. This principle underlies folk
remedies such as Tiger Balm or Sloan’s
Liniment as well as more modern prepara-
tions such as NeurogesX’s skin patch for
peripheral neuropathic pain.
In 2007, Woolf’s team reported a new
twist on this time-tested method. They
found that a combined injection of capsa-Chemistry & Biology 16, October 30, 2009icin and QX-314, a positively charged
molecule derived from lidocaine, had
a powerful analgesic effect. Because of
its size and charge, QX-314 can’t
penetrate through the neural membrane
by itself. But when TRPV1 channels are
opened using capsaicin, QX-314 can
diffuse through them into the nerve and
block its sodium channels. ‘‘You can use
the TRP channel as a way of getting a large
cationic molecule into a specific cell,’’
says Woolf. Since these channels are
found predominantly on pain-sensing
nerves, other functions will not be disrup-
ted. But the patient will suffer an initial
burning sensation due to capsaicin.
Fortunately, it now turns out that lidocaine
too can open the TRPV1 channel and,
unlike capsaicin, it doesn’t burn. ‘‘If you
inject lidocaine in combination with QX-
314, you have a transient period of nonse-
lective block of all nerves in the vicinity,
followed by many hours of selective block
of the pain fibers alone,’’ says Woolf. ‘‘The
lucky break was that lidocaine turned out
to be a TRPV1 agonist.’’ Harvard Medical
School has licensed the approach to
Endo Pharmaceuticals, who are expected
to start Phase I trials late next year.
Besides the ones described above,
researchers worldwide are developing
a vast array of other molecules targeting
nearly every step in the pain pathway.
Researchers express cautious optimism
that at least a few of these new
compounds will eventually bring relief to
chronic sufferers. Driving the flurry of
new efforts is a changing view of the
phenomenon of chronic pain. ‘‘We used
to think that chronic pain was the
symptom of an underlying problem,’’
says Dray. ‘‘We now realize that it is
a neurological disease process, just like
schizophrenia or Alzheimer, with long-
lasting changes in nerve biochemistry
and connections.’’
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